Search results
Showing 91 to 105 of 138 results for chronic heart failure
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department
Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)
NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay).
This guideline sets out an antimicrobial prescribing strategy for acute cough associated with an upper respiratory tract infection or acute bronchitis in adults, young people and children. It aims to limit antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (HTG553)
Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke.
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Intrapartum care: existing medical conditions and obstetric complications (QS192)
This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.
View quality statements for QS192Show all sections
Sections for QS192
- Quality statements
- Quality statement 1: Involving women in care planning
- Quality statement 2: Composition of the multidisciplinary team
- Quality statement 3: Heart disease – risk assessment
- Quality statement 4: Assessment and antibiotic treatment for suspected sepsis
- Quality statement 5: Women with no antenatal care
- Update information
- About this quality standard
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .